Back    Zoom +    Zoom -
恒瑞醫藥(01276.HK)子公司HRS-7156片臨床試驗獲批
Recommend
4
Positive
8
Negative
1
aacat by AASTOCKS
Open a new trading account to get NVDA share!
恒瑞醫藥(01276.HK)(600276.SH)公布，子公司山東盛迪HRS-7156片藥物臨床試驗獲國家藥品監督管理局批准，申請適應症為心力衰竭。HRS-7156片是公司自主研發的1類新藥，至今累計研發投入約3,760萬人民幣。(de/d)

AASTOCKS新聞
Switch to Auto-Translated Version
  • Remark
  • (1) HK Indices are real time
Home|RT Quote|Market|News|Indices
Feedback|Disclaimer
View: Mobile|Desktop
Lang: 繁|简|EN
Back To Top
Contact Us
Email: support@aastocks.com